Routine clinical use of alemtuzumab in patients with heavily pretreated B-cell chronic lymphocytic leukemia: a nation-wide retrospective study in Austria.

Michael Fiegl; Andreas Falkner; Georg Hopfinger; Stefan Brugger; August Zabernigg; Franz Bauer; Ferdinand Haslbauer; Dita Demirtas; Peter Grossschmidt; Georg Tatzreiter; Günther Gastl; Richard Greil

doi:10.1002/cncr.22263

Routine clinical use of alemtuzumab in patients with heavily pretreated B-cell chronic lymphocytic leukemia: a nation-wide retrospective study in Austria.

Michael Fiegl, Andreas Falkner, Georg Hopfinger (Co-author), Stefan Brugger, August Zabernigg, Franz Bauer, Ferdinand Haslbauer, Dita Demirtas, Peter Grossschmidt, Georg Tatzreiter, Günther Gastl, Richard Greil (Last author)

Department of Internal Medicine III - Division of Hematology, Medical Oncology, Hemostaseology, Rheumatology, Infectiology and Oncologic Center

Research output: Contribution to journal › Original Article › peer-review

33 Citations (Web of Science)

Original language	English
Pages (from-to)	2408-2416
Journal	CANCER
Volume	107
Issue number	10
DOIs	https://doi.org/10.1002/cncr.22263
Publication status	Published - 2006

Keywords

PHASE-II TRIAL
FLUDARABINE
CAMPATH-1H
THERAPY
COMBINATION
CLL
CYCLOPHOSPHAMIDE
GUIDELINES
ANTIBODIES
REGIMEN

Access to Document

10.1002/cncr.22263

Cite this

Fiegl, M., Falkner, A., Hopfinger, G., Brugger, S., Zabernigg, A., Bauer, F., Haslbauer, F., Demirtas, D., Grossschmidt, P., Tatzreiter, G., Gastl, G., & Greil, R. (2006). Routine clinical use of alemtuzumab in patients with heavily pretreated B-cell chronic lymphocytic leukemia: a nation-wide retrospective study in Austria. CANCER, 107(10), 2408-2416. https://doi.org/10.1002/cncr.22263

@article{fd40d188511f4944a8cfd57ab83f78f4,

title = "Routine clinical use of alemtuzumab in patients with heavily pretreated B-cell chronic lymphocytic leukemia: a nation-wide retrospective study in Austria.",

keywords = "PHASE-II TRIAL, FLUDARABINE, CAMPATH-1H, THERAPY, COMBINATION, CLL, CYCLOPHOSPHAMIDE, GUIDELINES, ANTIBODIES, REGIMEN",

author = "Michael Fiegl and Andreas Falkner and Georg Hopfinger and Stefan Brugger and August Zabernigg and Franz Bauer and Ferdinand Haslbauer and Dita Demirtas and Peter Grossschmidt and Georg Tatzreiter and G{\"u}nther Gastl and Richard Greil",

note = "Department of Internal Medicine III, University Hospital of Salzburg, Salzburg, Austria",

year = "2006",

doi = "10.1002/cncr.22263",

language = "English",

volume = "107",

pages = "2408--2416",

journal = "CANCER",

issn = "0008-543X",

publisher = "Wiley Verlag ",

number = "10",

}

Fiegl, M, Falkner, A, Hopfinger, G, Brugger, S, Zabernigg, A, Bauer, F, Haslbauer, F, Demirtas, D, Grossschmidt, P, Tatzreiter, G, Gastl, G & Greil, R 2006, 'Routine clinical use of alemtuzumab in patients with heavily pretreated B-cell chronic lymphocytic leukemia: a nation-wide retrospective study in Austria.', CANCER, vol. 107, no. 10, pp. 2408-2416. https://doi.org/10.1002/cncr.22263

TY - JOUR

T1 - Routine clinical use of alemtuzumab in patients with heavily pretreated B-cell chronic lymphocytic leukemia: a nation-wide retrospective study in Austria.

AU - Fiegl, Michael

AU - Falkner, Andreas

AU - Hopfinger, Georg

AU - Brugger, Stefan

AU - Zabernigg, August

AU - Bauer, Franz

AU - Haslbauer, Ferdinand

AU - Demirtas, Dita

AU - Grossschmidt, Peter

AU - Tatzreiter, Georg

AU - Gastl, Günther

AU - Greil, Richard

N1 - Department of Internal Medicine III, University Hospital of Salzburg, Salzburg, Austria

PY - 2006

Y1 - 2006

KW - PHASE-II TRIAL

KW - FLUDARABINE

KW - CAMPATH-1H

KW - THERAPY

KW - COMBINATION

KW - CLL

KW - CYCLOPHOSPHAMIDE

KW - GUIDELINES

KW - ANTIBODIES

KW - REGIMEN

U2 - 10.1002/cncr.22263

DO - 10.1002/cncr.22263

M3 - Original Article

C2 - 17054106

SN - 0008-543X

VL - 107

SP - 2408

EP - 2416

JO - CANCER

JF - CANCER

IS - 10

ER -